Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients

Fedyanin, Mikhail; Tryakin, А. А.; Rogov, V. A.; Ганичева, Л. М.; Frolov, M. Yu.; Tyulyandin, S. A.

doi:10.17650/2220-3478-2017-7-2-36-42

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Однако именно наиболее современные таргетные и иммунные противоопухолевые препараты существенно увеличили экономическую нагрузку на систему здравоохранения. С учетом высокой цены новых препаратов выбор оптимальной последовательности линий противоопухолевого лекарственного лечения этого заболевания крайне актуален [10][11][12][13].…”

Section: введение / Introductionunclassified

Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Objective: to perform a pharmacoeconomic evaluation of the effectiveness of therapies for metastatic colorectal cancer (mCRC) based on real practical data on medical help for patients with this disease.Material and methods. The authors performed a comparative cost-effectiveness analysis and the calculation of resource consumption in the application of several options of chemotherapy for mCRC: FOLFOX, FOLFIRI, and FOLFOXIRI; targeted therapy: FOLFOX + bevacizumab, FOLFOX + panitumumab, FOLFIRI + cetuximab, FOLFIRI + aflibercept, regorafenib monotherapy.Results. The cost-effectiveness parameter, calculated as a ratio of the cost of therapy to the median survival without progression, for chemotherapeutic schemes varied from 108 to 167 thousand rubles and for the targeted therapy schemes – from 223 to 930 thousand rubles. The calculation of resource consumption showed that in the case of a limited budget, 100% of patients can be treated by FOLFOX scheme, or 26% of patients by FOLFOX + panitumumab, or 47% of patients by FOLFOX + bevacizumab; and 100% of patients by FOLFIRI scheme or 11.5% of patients by FOLFIRI + cetuximab (aflibercept). Besides, it was established that in the case of a similar budget, 100% of patients with mCRC can be treated by chemotherapy schemes or a limited number of patients with regorafenib.Conclusion. The cost of targeted therapy significantly exceeds the cost of chemotherapeutic schemes. Still, considering the gross domestic product per capita in the Russian Federation, they can be an economically feasible investment and the optimum option of therapy

show abstract

Section: введение / Introductionunclassified

Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

Comparative pharmacoeconomic analysis of metastatic colorectal cancer treatment

Petukhova

Елисеева

Апанасевич

et al. 2021

Bulletin of the Russian Military Medical Academy

View full text Add to dashboard Cite

Every year, the pharmacological market offers new medicines to increase the survival rate and improve the quality of life of patients with cancer. However, while significantly exceeding the cost of existing methods of pharmacotherapy, new technologies often lead to only a small increased efficiency. Budget resources of health care dictate the need for a rational choice of pharmacotherapeutic options for malignant neoplasms that meet the principles of ensuring maximum results and accessibility for the entire population. An important role in solving this problem is played by such a direction of pharmacoeconomic analysis as the cost-effectiveness method. Colorectal cancer is one of the three oncological diseases that cause the greatest socio-economic burden for the state, which is associated with the highest costs of the Russian Federation health care system. Concurrently, in the last decade, a much more favorable prognosis has been identified for patients with metastatic colorectal cancer due to the development of effective approaches to antitumor pharmacotherapy. Conducting a pharmacoeconomic review that takes into account both clinical and economic indicators when using classic chemotherapy regimens and new targeted drugs will determine the effectiveness of finances that are spent to combat this malignancy. Additionally, the need to further individualize the therapy of patients suffering from metastatic colorectal cancer and lower prices for modern antitumor drugs is undeniable.

show abstract

Cost-effectiveness indicator for colorectal cancer therapy

Елисеева

Petukhova

2020

Tihookeanskij medicinskij žurnal

View full text Add to dashboard Cite

Contemporary data on different therapy schemes for colorectal cancer are presented from the point of view of “costeffectiveness” indicator. There is an information about Federal programs aimed at increasing annual healthcare financing connected with preventing and curing malignancies. The statistics of the annual growth in colon and rectum cancer rates is discussed. An actual problem of increasing number of resource-intensive medicines for oncology treatment is stated. This is the reason to analyze cost-effectiveness.

show abstract

Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients

Abstract: О б з о р л и т е р а т у р ы

Cited by 3 publications

References 28 publications

Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer

Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer

Comparative pharmacoeconomic analysis of metastatic colorectal cancer treatment

Cost-effectiveness indicator for colorectal cancer therapy

Contact Info

Product

Resources

About